Viracta Therapeutics Inc (SNSS)
Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development of targeted inhibitors for the treatment of hematologic and solid cancers. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology and conducting clinical trials. Co.'s primary program is vecabrutinib, a selective non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.
|
Free SNSS Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Buy (2.67 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|